Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05743842 · ClinicalTrials.gov registry record · NA

TriNav Infusion System for the Evaluation of Fidelity Between 99mTc-MAA and Y90-Microspheres Hepatic Distribution for Dosimetry Treatment Planning

A NA study of Liver Cancer, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
NA
Development phase
19
Enrollment target
1
Study location

NCT05743842 is a NA study of Liver Cancer that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 19 participants, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05743842, a NA study of Liver Cancer, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
19 participants
Enrollment target
1
Study location

Study Summary

To learn if using the TriNav Infusion System (TriNav catheter) for the injection of the surrogate/test dose during the planning part of the radioembolization procedure and your actual treatment with the radioactive microspheres match each other better than the standard catheter.

Conditions Studied

Interventions

  • DEVICE TriSalus™ TriNav™Infusion System
  • DIAGNOSTIC_TEST Angiogram
  • PROCEDURE Y90-radioembolization procedure

Study Locations (1)

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2023-03-14
Est. Completion 2027-12-31
Phase NA

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

What the Registry Record Tells You About NCT05743842

The ClinicalTrials.gov registry entry for NCT05743842 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (96% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Liver Cancer appearing as the primary indexed condition, and to 3 interventions - of which TriSalus™ TriNav™Infusion System is the first listed.

NCT05743842 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT05743842 about?

NCT05743842 is a clinical study titled "TriNav Infusion System for the Evaluation of Fidelity Between 99mTc-MAA and Y90-Microspheres Hepatic Distribution for Dosimetry Treatment Planning". To learn if using the TriNav Infusion System (TriNav catheter) for the injection of the surrogate/test dose during the planning part of the radioembolization procedure and your actual treatment with the radioactive microspheres match each other better than the standard catheter.

What is the current status of trial NCT05743842?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 19 participants. The study started on 2023-03-14. Estimated completion is 2027-12-31.

What conditions does trial NCT05743842 study?

This clinical trial studies the following conditions: Liver Cancer.

What interventions are being tested in trial NCT05743842?

The interventions under investigation include: TriSalus™ TriNav™Infusion System (DEVICE), Angiogram (DIAGNOSTIC_TEST), Y90-radioembolization procedure (PROCEDURE).

Who is sponsoring clinical trial NCT05743842?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05743842 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Liver Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.